Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 4
Ce profil est validé par 4 label.

Company

Vaxxel

Vaxxel_logo
43
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Vaxxel is a pre-clinical-stage company developing vaccines against bronchiolitis and viral pneumonia: Metapneumovirus (hMPV) and respiratory Syncytial Virus (hRSV) based on a proprietary cell line and technology platform.

Villeurbanne, Auvergne-Rhône-Alpes, France

Send a message

Anglais

Vaxxel

Anglais

Vaxxel is a spin off from Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), by Pr. Guy Boivin of the University of Laval (Quebec), and by Denis Cavert, President of Vaxxel. Vaxxel develops live-attenuated vaccines against Metapneumovirus and against the Respiratory Syncytial Virus based on the Metavac® vaccine platform. This platform has been funded...

See more

Vaxxel is a spin off from Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), by Pr. Guy Boivin of the University of Laval (Quebec), and by Denis Cavert, President of Vaxxel. Vaxxel develops live-attenuated vaccines against Metapneumovirus and against the Respiratory Syncytial Virus based on the Metavac® vaccine platform. This platform has been funded and licensed by Pulsalys and supported by Lyon Ingénierie Projets (LIP), a subsidiary of UCBL. Proof of Concept of the first monovalent vaccine candidate against the Metapneumovirus has been demonstrated on both animal and human ex vivo models. The company is a recipient of the 2019 i-Lab award, organized by the Ministry of Higher Education, Research and Innovation in partnership with Bpifrance, and has also received “FrenchTech seed” label.

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

AP-HP
14 Entities
SATT Pulsalys
7 Entities
Angels Santé
23 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Members
France Angels
France Angels is a Nationale Federation of Business Angels. Nationale federation that federates, represents and promotes French Business Angels.
489 Members
Les Deeptech
Les Deeptech, c’est la communauté qui rassemble les startups deeptech françaises et les investisseurs désirant développer des relations business avec elles.
358 Members
SATT
SATTs are Societies By Simplified Actions created by several public research centers as part of the "Investments for the Future" Program (french PIA); within the commercialization department.
302 Members